Pharmaceuticals and Digital Health: Evidence from Data-driven Insights on the Insulin Market

Léa Bignon

No 26-1743, TSE Working Papers from Toulouse School of Economics (TSE)

Abstract: Digital health technologies, such as Continuous Glucose Monitors (CGMs), are transforming the availability of patient-level data, potentially influencing other healthcare markets. This paper examines how CGMs influence the insulin market, shedding light on the impact of digital health technologies on phar maceutical demand, pricing, and innovation incentives. I develop and estimate a tractable model of supply and demand for insulin, embedding: (i) patient specific learning about treatment performance through CGMs, (ii) physician level learning about new insulin products from patient experiences, and (iii) price bargaining between pharmaceutical companies and the regulator. Using medical claims data from France, I find that CGMs’ patient-specific informa tion steered insulin demand toward newer products, with limited spillover to nonusers. Manufacturers of drugs that benefited from higher perceived qual ity could negotiate higher prices. My findings indicate that introducing these newly observable product attributes into pharmaceutical demand shifts the rel ative profitability of drug innovation strategies, thereby shaping the direction of future pharmaceutical innovation.

Date: 2026-05-04
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.tse-fr.eu/sites/default/files/TSE/docu ... 2026/wp_tse_1743.pdf Full Text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:tse:wpaper:131698

Access Statistics for this paper

More papers in TSE Working Papers from Toulouse School of Economics (TSE) Contact information at EDIRC.
Bibliographic data for series maintained by ().